This company has shut down. Kynos Therapeutics is no longer operating — its last tracked round was a Seed in 2022.
Explore the Startup GraveyardKynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism.
Kynos Therapeutics has raised $8.5M in total funding. The most recent round was Seed. The last funding was announced in April 2022.
Kynos Therapeutics's investors include IP Group, Epidarex Capital, Innovate UK, Scottish Enterprise.
Kynos Therapeutics is headquartered in Edinburgh, United Kingdom.
Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism.
Kynos Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kynos Therapeutics — Funding & Investors." VCBacked, April 7, 2022, https://www.vcbacked.co/company/kynos-therapeutics. Accessed August 13, 2026.
VCBacked. (2022). Kynos Therapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/kynos-therapeutics
{{cite web |title=Kynos Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/kynos-therapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated